How much bloating in the irritable bowel syndrome?

Pop, Lucian Liviu; Mureşan, I; Dumitraşcu, Dan L.

doi:10.2478/rjim-2018-0017

Cited by 5 publications

(6 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…1 Similar data has been reported from Romania. 13 These data suggested that besides recurrent abdominal pain, abdominal bloating should also be included in the IBS diagnostic criteria, while the pain component in IBS may be de-emphasized in Asia.…”

Section: Team 1: Symptoms and Epidemiologymentioning

confidence: 99%

Second Asian Consensus on Irritable Bowel Syndrome

Gwee

Gonlachanvit

Ghoshal

et al. 2019

J Neurogastroenterol Motil

View full text Add to dashboard Cite

Background/Aims There has been major progress in our understanding of the irritable bowel syndrome (IBS), and novel treatment classes have emerged. The Rome IV guidelines were published in 2016 and together with the growing body of Asian data on IBS, we felt it is timely to update the Asian IBS Consensus. Methods Key opinion leaders from Asian countries were organized into 4 teams to review 4 themes: symptoms and epidemiology, pathophysiology, diagnosis and investigations, and lifestyle modifications and treatments. The consensus development process was carried out by using a modified Delphi method. Results Thirty-seven statements were developed. Asian data substantiate the current global viewpoint that IBS is a disorder of gut-brain interaction. Socio-cultural and environmental factors in Asia appear to influence the greater overlap between IBS and upper gastrointestinal symptoms. New classes of treatments comprising low fermentable oligo-, di-, monosacharides, and polyols diet, probiotics, non-absorbable antibiotics, and secretagogues have good evidence base for their efficacy. Conclusions Our consensus is that all patients with functional gastrointestinal disorders should be evaluated comprehensively with a view to holistic management. Physicians should be encouraged to take a positive attitude to the treatment outcomes for IBS patients.

show abstract

Section: Team 1: Symptoms and Epidemiologymentioning

confidence: 99%

Second Asian Consensus on Irritable Bowel Syndrome

Gwee

Gonlachanvit

Ghoshal

et al. 2019

J Neurogastroenterol Motil

View full text Add to dashboard Cite

show abstract

“…Bloating in English is defined as the subjective sensation of an increase in abdominal girth, while abdominal distension is the visible or true increase in abdominal girth 1 . The first one is a symptom, while the second one is both a symptom and a clinical sign.…”

Section: Introductionmentioning

confidence: 99%

“…

…”

mentioning

confidence: 99%

Pictograms are more effective than verbal descriptors in Spanish for bloating and distension

Rábago

Bonilla

Escamilla-Diego

et al. 2022

Neurogastroenterology Motil

View full text Add to dashboard Cite

Bloating in English is defined as the subjective sensation of an increase in abdominal girth, while abdominal distension is the visible or true increase in abdominal girth. 1 The first one is a symptom, while the second one is both a symptom and a clinical sign. In addition, bloating and distension can coexist and they are very commonly reported by patients and subjects in the general population. 2 Their underlying mechanism is not completely elucidated; however, bloating may be related to gut hypersensitivity, while abdominal distension can be related to an increment in intraluminal gas, as well as a behavioral response, featuring a diaphragmatic contraction and descent with anterior wall protrusion known as abdomino-phrenic dyssynergia. 2 Earlier epidemiological studies in North America

show abstract

“…Median percentage of days with bloating was lower in patients with IBS-C in the B. clausii group versus placebo. Bloating is common in IBS [ 46 ]. However, two RCTs showed that other probiotics did not impact the rate of bloating versus placebo (relative risk 0.32; 95% CI 0.04–2.56) [ 40 ].…”

Section: Discussionmentioning

confidence: 99%

Efficacy and Safety of the Adjuvant Use of Probiotic Bacillus clausii Strains in Pediatric Irritable Bowel Syndrome: A Randomized, Double-Blind, Placebo-Controlled Study

Vázquez-Frías

Consuelo-Sánchez

Acosta-Rodríguez-Bueno

et al. 2022

Pediatr Drugs

View full text Add to dashboard Cite

Objectives Current irritable bowel syndrome (IBS) treatments have limited efficacy and probiotics like Bacillus clausii ( B. clausii ) were found to be effective in the management of several gastrointestinal disorders. This phase III trial assessed the efficacy and safety of adding B. clausii (four strains: O/C, N/R, SIN, T), versus placebo, to conventional treatment of pediatric IBS in Mexico. Methods Patients aged 6–17 years 11 months with IBS (Rome IV) for at least 2 months were randomized to receive either B. clausii (oral suspension, total dose 4 billion spores/day) or placebo once daily for 8 weeks. All patients also received conventional treatment. The primary endpoint was the difference in the proportion of patients with clinical improvements at Week 8 (Global Assessment Questions [GAQ]). Secondary endpoints included responders by Subject’s Global Assessment of Relief for Children with IBS (SGARC); number/consistency of stools; abdominal distention/bloating; abdominal pain/intensity; and IBS behavior. Results 73.6% (95% confidence interval [CI] 67.3–80.0; B. clausii n = 129) and 78.5% (95% CI 72.5–84.4; placebo n = 130) of patients had symptom improvement ( p = 0.8182). For Week 8 SGARC, 19.2% ( B. clausii ) and 20.9% (placebo) reported complete symptom relief. Stool evaluations, bloating, abdominal pain/intensity, and IBS behavior were similar between groups. Both treatments were well tolerated. Conclusion No significant differences in efficacy between B. clausii and placebo were demonstrated in addition to conventional treatment. The sample size calculation was based on an expected placebo/conventional treatment response of 30–40%. However, the actual treatment response observed was 80% and, thus, a study with larger population would be warranted. In addition, this study was conducted during the COVID-19 pandemic, when such controlled social conditions may have resulted in better diet, greater family stability, less psychological stress, and lower risk of infections exacerbating IBS, thereby improving symptoms in both groups. EudraCT number 2018-004519-31. Supplementary Information The online version contains supplementary material available at 10.1007/s40272-022-00536-9.

show abstract

How much bloating in the irritable bowel syndrome?

Cited by 5 publications

References 39 publications

Second Asian Consensus on Irritable Bowel Syndrome

Second Asian Consensus on Irritable Bowel Syndrome

Pictograms are more effective than verbal descriptors in Spanish for bloating and distension

Efficacy and Safety of the Adjuvant Use of Probiotic Bacillus clausii Strains in Pediatric Irritable Bowel Syndrome: A Randomized, Double-Blind, Placebo-Controlled Study

Contact Info

Product

Resources

About